We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Smith & Nephew plc (SN.) Ordinary USD0.20

Sell:1,101.50p Buy:1,102.50p 0 Change: 6.00p (0.55%)
FTSE 100:0.47%
Market closed Prices as at close on 23 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 6.00p (0.55%)
Market closed Prices as at close on 23 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 6.00p (0.55%)
Market closed Prices as at close on 23 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

Contact details

Building 5, Croxley Park, Hatters Lane
WD18 8YE
United Kingdom
+44 (020) 74017646

Important dates

Future events
Quarter 2 results 01 August 2024 01/08/24
Past events
Final dividend payment date 22 May 2024 22/05/24
AGM 01 May 2024 01/05/24
Trading Announcement 01 May 2024 01/05/24
Trading Announcement 23 April 2024 23/04/24
Final ex-dividend date 01 April 2024 01/04/24
Final ex-dividend date 28 March 2024 28/03/24
Annual report 11 March 2024 11/03/24
Final results 27 February 2024 27/02/24
Trading Announcement 02 November 2023 02/11/23
Quarter 3 results 02 November 2023 02/11/23
Interim dividend payment date 01 November 2023 01/11/23
Interim ex-dividend date 05 October 2023 05/10/23
Interim results 03 August 2023 03/08/23
Quarter 2 results 03 August 2023 03/08/23
Trading Announcement 03 August 2023 03/08/23

General stock information

Market cap:
£9.61 billion
Shares in issue:
871.95 million
Health Care Equipment & Services
London Stock Exchange
Sterling pence
FTSE 100,FTSE techMARK 100,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • Deepak Nath
    Chief Executive Officer, Executive Director
  • John Rogers
    Chief Financial Officer, Executive Director
  • Paul Connolly
    President - Global Operations
  • Craig Gaffin
    President - Orthopaedics
  • Rohit Kashyap
    President - Advanced Wound Management and Global Commercial Operations
  • Vasant Padmanabhan
    President - Research and Development
  • Scott Schaffner
    President - Sports Medicine
  • Elga Lohler
    Chief Human Resource Officer
  • Alison Parkes
    Chief Compliance Officer
  • Helen Barraclough
    Group General Counsel, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.